Colivelin (TFA)

Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3?in vitro[1]. Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease[2]. Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury[1].

O=C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N1[C@@H](CCC1)C(N[C@@H](C)C(N2[C@@H](CCC2)C(N[C@@H](C)C(NCC(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CO)N.OC(C(F)(F)F)=O

[1]Chiba T, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci. 2005 Nov 2;25(44):10252-61.|[2]Zhao H, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway.Neuroscience. 2019 Sep 15;416:198-206.|[3]Pan Z, et al. Upregulation of HSP72 attenuates tendon adhesion by regulating fibroblast proliferation and collagen production via blockade of the STAT3 signaling pathway.Cell Signal. 2020 Mar 18:109606.|[4]Fang YY, et al. MFG-E8 alleviates oxygen-glucose deprivation-induced neuronal cell apoptosis by STAT3 regulating the selective polarization of microglia. Int J Neurosci. 2020 Mar 12:1-10.|[5]Chiu WC, et al. The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways. PLoS One. 2016 Nov 22;11(11):e0166453.Ann Transl Med. 2020 Nov;8(21):1346.|Antiviral Res. January 2022, 105228.|Biochem Cell Biol. 2022 Nov 1.|Biochem Cell Biol. 2022 Oct 20.|Biomed Pharmacother. 2020 Nov;131:110541.|Biomol Biomed. 2024 Aug 2.|Cell Commun Signal. 2021 Nov 16;19(1):115.|Exp Ther Med. March 1, 2022.|Frigid Zone Medicine. 20 May 2022.|Front Mol Biosci. 2021 Jun 18;8:654766.|Inflamm Bowel Dis. 2023 Jun 19;izad099.|Int Immunopharmacol. 2024 Apr 25:133:112126.|Int Immunopharmacol. 2024 Oct 18;143(Pt 2):113416.|Int J Biol Sci. 2023 Mar.|Int J Neurosci. 2021 Jan;131(1):15-24.|J Agric Food Chem. 2021 Jul 6.|J Inflamm Res. 24 May 2022.|J Nanobiotechnology. 2024 Jun 19;22(1):345.|Nat Commun. 2021 Nov 25;12(1):6891.|PeerJ. 2022 Sep 28;10:e14086.|Phytomedicine. 2022: 154551.|Phytomedicine. 2023 Apr 3, 154799.|Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2122099119.|Research Square Preprint. 2020 Dec.|Vascul Pharmacol. 2024 Jul 17:107411.|Aging. 2020 May 15;12(10):9066-9084.|Biochim Biophys Acta Mol Basis Dis. 2023 Dec 6:166979.|Cancer Immunol Immunother. 2022 Jun 20.|Cell Signal. 2020 Jul;71:109606.|CNS Neurosci Ther. 2023 Oct 23.|Commun Biol. 2022 Dec 1;5(1):1316.|Drug Dev Res. 2022 Oct 2.|Ecotoxicol Environ Saf. 2024 Aug 12:283:116857.|Free Radic Biol Med. 2024 Aug 28:S0891-5849(24)00630-0.|Inflammation. 2024 Jun 17.|Int J Mol Sci. 2024 Mar 3, 25(5), 2950.|Int J Nanomedicine. 2023 Nov 28.|J Ethnopharmacol. 2024 Sep 13:118829.|J Nanobiotechnology. 2024 Aug 24;22(1):509.|J Nanobiotechnology. 2024 Jul 11;22(1):409.|J Nat Med. 2020 Jun;74(3):533-544. |J Physiol Sci. 2024 Feb 16.|Mol Biol Rep. 2024 Jan 22;51(1):176.|Oncol Rep. 2024 May;51(5):71.|Phytomedicine. 2024 Mar 22, 155563.|Redox Biol. 2023 Nov 7, 102956.|Sci Transl Med. 2021 Oct 6;13(614):eabg6428.|SSRN. 2024 Apr 7.|World J Stem Cells. 2024 Nov 26;16(11):906-925.